Data gathered: April 15
AI Stock Analysis - Nkarta (NKTX)
Analysis generated July 12, 2024. Powered by Chat GPT.
Nkarta, Inc. is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies to treat cancer. Their innovative approach to harnessing NK cells positions them as a promising player in the rapidly advancing field of cell therapy. However, as with many biotechnology firms, Nkarta’s financial performance can be volatile given the high research and development costs and the long timelines associated with clinical trials.
Stock Alerts - Nkarta (NKTX)
 |
Nkarta | April 14 Price is up by 7.6% in the last 24h. |
|
Nkarta | April 10 Price is down by -5.1% in the last 24h. |
|
Nkarta | April 9 Price is down by -5.6% in the last 24h. |
|
Nkarta | April 8 Price is down by -5.1% in the last 24h. |
Alternative Data for Nkarta
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 21 | Sign up | Sign up | Sign up |
| Patents | 17 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 10 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,175 | Sign up | Sign up | Sign up |
| Twitter Followers | 360 | Sign up | Sign up | Sign up |
| Twitter Mentions | 7 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 77 | Sign up | Sign up | Sign up |
| Linkedin Employees | 160 | Sign up | Sign up | Sign up |
About Nkarta
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment.
| Price | $1.70 |
| Target Price | Sign up |
| Volume | 684,870 |
| Market Cap | $112M |
| Year Range | $1.37 - $6.51 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Nkarta (NKTX) Upgraded to Buy: Here's WhyApril 14 - Yahoo |
 |
Sei Investments Co. Purchases Shares of 22,788 Nkarta, Inc. (NASDAQ:NKTX)April 13 - ETF Daily News |
 |
Needham & Company LLC Reiterates “Buy” Rating for Nkarta (NASDAQ:NKTX)April 11 - ETF Daily News |
Nkarta to Participate in an April Investor ConferenceApril 1 - GlobeNewswire |
|
|
Q1 Earnings Estimate for Nkarta Issued By HC WainwrightMarch 31 - ETF Daily News |
|
William Blair Issues Pessimistic Outlook for Nkarta EarningsMarch 31 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 0 | 0 | 0 | -26M | -29M | -0.350 |
| Q3 '24 | 0 | 0 | 0 | -28M | -31M | -0.390 |
| Q2 '24 | 0 | 2.3M | -2.3M | -25M | -28M | -0.340 |
| Q1 '24 | 0 | 2.3M | -2.3M | -30M | -31M | -0.580 |
| Q4 '23 | 11M | 2.3M | 8.3M | -28M | -26M | -0.570 |
Insider Transactions View All
| Hager Alicia J. filed to sell 146,735 shares at $2.2. January 17 '25 |
| Brandenberger Ralph filed to sell 124,796 shares at $2.2. January 17 '25 |
| Levin Alyssa filed to sell 102,662 shares at $2.2. January 17 '25 |
| Shook David filed to sell 190,955 shares at $2.2. January 17 '25 |
| HASTINGS PAUL J filed to sell 319,859 shares at $2.2. January 17 '25 |
Similar companies
Read more about Nkarta (NKTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Nkarta?
The Market Cap of Nkarta is $112M.
What is the current stock price of Nkarta?
Currently, the price of one share of Nkarta stock is $1.70.
How can I analyze the NKTX stock price chart for investment decisions?
The NKTX stock price chart above provides a comprehensive visual representation of Nkarta's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Nkarta shares. Our platform offers an up-to-date NKTX stock price chart, along with technical data analysis and alternative data insights.
Does NKTX offer dividends to its shareholders?
As of our latest update, Nkarta (NKTX) does not offer dividends to its shareholders. Investors interested in Nkarta should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Nkarta?
Some of the similar stocks of Nkarta are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.